Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Cycloserine + Virtual Reality Exposure therapy
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
D-Cycloserine + Virtual Reality Exposure therapy is a combination treatment protocol developed and evaluated by Weill Medical College of Cornell University for the treatment of post-traumatic stress disorder (PTSD), particularly in military veterans. D-Cycloserine (DCS) is a small molecule antibiotic repurposed as a cognitive enhancer that acts as a partial agonist at the glycine binding site of the N-methyl-D-aspartate (NMDA) receptor. By facilitating NMDA receptor-mediated glutamatergic neurotransmission, DCS enhances fear extinction learning and memory consolidation when administered prior to exposure therapy. Virtual Reality Exposure (VRE) provides a controlled, immersive environment for patients to confront and process traumatic memories. Clinical trials led by Dr. JoAnn Difede have demonstrated that the adjunctive use of DCS with VRE can accelerate and enhance the therapeutic effects of exposure therapy, showing particular efficacy in reducing symptoms like irritability and sleep disturbances.
- Brand names
- Seromycin
- Other names
- D-Cycloserine + VREDCS + VREVirtual Reality Exposure therapy with D-Cycloserine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on D-Cycloserine + Virtual Reality Exposure therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-Cycloserine + Virtual Reality Exposure therapy.